Eli Lilly’s shares have surged 750 per cent over five years. Novo Nordisk’s are up about 360 per cent in the same period.

The novel GLP-1 receptor agonists will likely reduce the need for CABG and improve surgical outcomes, several argue.

Speakers from across the care continuum will discuss legislative updates, glucagon-like peptide-1 (GLP-1) use for weight management, and more at this year’s AMCP Nexus.

As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S.

The University of California, Davis today announced an expanded collaboration with the BioInnovation Institute (BII) to ...

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

The risk for kidney function decline is lower among new users of sodium glucose cotransporter-2 inhibitors (SGLT2i) vs glucagon-like peptide 1 receptor agonists (GLP-1RA), a real-world study of ...

U.S. Senator Elizabeth Warren has asked antitrust regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk ...

If there’s a diet, Janet McCaskill says, she’s done it. “I’ve tried WeightWatchers. I’ve tried keto. I’ve gone to a ...

Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over ...

BrucePac is recalling approximately 9,986,245 pounds of ready-to-eat meat and poultry products that may be adulterated with ...

WW stock popped after announcing a new compounded semaglutide product to benefit from the current shortage of weight loss ...